An investigation for investors in Insmed Incorporated (NASDAQ:INSM) shares over potential securities laws violations by Insmed was announced and NASDAQ:INSM stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 06/14/2016 -- Insmed Incorporated is under investigation concerning possible securities laws violations. The investigation was announced for investors in NASDAQ:INSM shares in connection certain financial statements made by Insmed.
Investors who purchased shares of Insmed Incorporated (NASDAQ:INSM), have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether certain statements by Insmed regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On June 8, 2016, post-market, Insmed Incorporated announced that it had withdrawn a European marketing application submitted to the European Medicines Agency for its lung disease drug Arikayce. Insmed Incorporated stated that the marketing application was based on data from a mid-stage clinical study that didn't support enough evidence for an approval from the European Medicines Agency. Insmed Incorporated stated that the Company will resubmit the application when data is available from a later study.
Shares of Insmed Incorporated (NASDAQ:INSM) declined to $9.95 per share on June 9, 2016.
On June 10, 2016, NASDAQ:INSM shares closed at $10.88 per share.
Those who purchased shares of Insmed Incorporated have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego